Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908

Salmonella typhi vaccine strain CVD 908 can deliver heterologous antigens to the host immune system following mucosal immunization. Stable expression of foreign proteins in Salmonella cells often requires antigen-specific engineering strategies. Fusion of antigens to stabilizing proteins has proven to be a successful strategy for rescuing otherwise unstable proteins. We designed plasmids to allow the fusion of antigens to the amino terminus or carboxyl terminus of fragment C of tetanus toxin, separated by a 4-amino-acid hinge region. Towards the ultimate goal of developing a live oral diphtheria-pertussis-tetanus vaccine, we used these plasmids to stably express the S1 subunit of pertussis toxin in CVD 908. Driven by the anaerobically inducible nirB promoter, the S1 subunit alone was expressed poorly in Salmonella cytoplasm. In contrast, hybrid proteins with S1 fused to either the amino or carboxyl terminus of fragment C were expressed at a high level in CVD 908 and were recognized in Western blot (immunoblot) analysis by monoclonal antibodies directed to S1 and to fragment C. Mice were immunized by the oral or intranasal routes with CVD 908 derivatives harboring these recombinant plasmids. All fusion proteins elicited serum antibody responses to fragment C following intranasal immunization, whereas oral inoculation did not. The configuration of antigens constituting the fusion was critical; S1 fused to the amino terminus of fragment C was less effective than S1 fused to the carboxyl terminus in generating anti-fragment C antibodies. CVD 908 expressing truncated S1 fused to the carboxyl terminus of fragment C elicited neutralizing serum pertussis antitoxin following intranasal immunization of mice.

[1]  M. Levine,et al.  A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. , 1997, Vaccine.

[2]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[3]  J. Eldridge,et al.  Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres , 1995, Infection and immunity.

[4]  R. Rappuoli,et al.  Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. , 1995, Vaccine.

[5]  G. Lewis,et al.  Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. , 1995, Vaccine.

[6]  G. Dougan,et al.  Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. , 1994, Journal of immunology.

[7]  C. Locht,et al.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein , 1994, Infection and immunity.

[8]  D. Cohen,et al.  Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models , 1993, Infection and immunity.

[9]  R. Rappuoli,et al.  Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin , 1992, Infection and immunity.

[10]  Ian G. Charles,et al.  Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis , 1992, Infection and immunity.

[11]  K. Timmis,et al.  Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit , 1992, Infection and immunity.

[12]  I. Charles,et al.  Use of the nirB Promoter to Direct the Stable Expression of Heterologous Antigens in Salmonella Oral Vaccine Strains: Development of a Single–Dose Oral Tetanus Vaccine , 1992, Bio/Technology.

[13]  M. Levine,et al.  Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. , 1992, Vaccine.

[14]  K. Timmis,et al.  Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis , 1991, Infection and immunity.

[15]  G. Dougan,et al.  Construction of genetically defined double aro mutants of Salmonella typhi. , 1991, Vaccine.

[16]  H. Sato,et al.  Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies , 1991, Infection and immunity.

[17]  I. Charles,et al.  High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. , 1991, Nucleic acids research.

[18]  M. Kimura Japanese clinical experiences with acellular pertussis vaccines. , 1991, Developments in biological standardization.

[19]  H. Sato,et al.  Protective activities in mice of monoclonal antibodies against pertussis toxin , 1990, Infection and immunity.

[20]  C. Locht,et al.  Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin , 1990, Infection and immunity.

[21]  N. Fairweather,et al.  Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier , 1990, Infection and immunity.

[22]  L. Nencioni,et al.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough , 1990, Infection and immunity.

[23]  S. Stibitz,et al.  Cloning and expression of functional fragment C of tetanus toxin , 1990, Infection and immunity.

[24]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[25]  K. J. Kim,et al.  Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. , 1989, Hybridoma.

[26]  S. Busby,et al.  Mutational analysis of the nucleotide sequence at the FNR-dependent nirB promoter in Escherichia coli. , 1989, Nucleic acids research.

[27]  R. Curtiss,et al.  Selective delivery of antigens by recombinant bacteria. , 1989, Current topics in microbiology and immunology.

[28]  P. Jayaraman,et al.  Location and sequence of the promoter of the gene for the NADH-dependent nitrite reductase of Escherichia coli and its regulation by oxygen, the Fnr protein and nitrite. , 1987, Journal of molecular biology.

[29]  G. Dougan,et al.  Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system , 1987, Parasite immunology.

[30]  A. Ferrante,et al.  Staphylococcus aureus-stimulated human mononuclear leucocyte-conditioned medium augments the basal and stimuli-induced neutrophil respiratory burst and degranulation. , 1987, Immunology.

[31]  C. Locht,et al.  Pertussis toxin gene: nucleotide sequence and genetic organization. , 1986, Science.

[32]  J. Chiba,et al.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections , 1984, Infection and immunity.

[33]  M. Pittman The concept of pertussis as a toxin‐mediated disease , 1984, Pediatric infectious disease.

[34]  T. Katada,et al.  The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. , 1983, Archives of biochemistry and biophysics.

[35]  M. Ui,et al.  A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. , 1983, The Journal of biological chemistry.

[36]  E. Hewlett,et al.  Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin , 1983, Infection and immunity.

[37]  T. Katada,et al.  Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. , 1982, Biochemistry.

[38]  B. Stocker,et al.  Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines , 1981, Nature.